China runs more stem cell clinical trials than any other country. For international patients seeking MSC therapy for diabetes, autoimmune disease, COPD, or anti-aging protocols, the Boao Lecheng special zone offers supervised clinical access to treatments not yet available in the West — at 60–80% below Swiss or US prices.
“Stem cell therapy” covers a broad spectrum. The same technology that has been standard medicine for blood cancers for decades is now showing measurable results in diabetes, autoimmune disease, COPD, and cellular ageing — but evidence strength varies significantly by application. Honest guidance requires knowing which category applies to your situation.
01
Haematopoietic Stem Cell Transplantation (HSCT)
Standard, proven medicine for blood cancers and bone marrow failure. China's Grade 3A centres perform tens of thousands annually at one-tenth the cost of the United States, with comparable outcomes data at leading institutions such as CAMS Tianjin, Ruijin Shanghai, and Nanfang Guangzhou.
02
Mesenchymal Stem Cell (MSC) Therapy
Advanced clinical-phase treatment for autoimmune conditions, diabetes, and chronic inflammatory disease. A 2021 systematic review in Stem Cell Reviews and Reports found MSC infusion reduced HbA1c by 1.2–2.1% in Type 2 diabetes patients across multiple randomised trials. Available in China via registered ChiCTR trials and at Boao Lecheng under special zone regulations.
03
Exosome & Anti-Aging Protocols
Wellness-oriented programmes targeting the hallmarks of cellular ageing — senescence, mitochondrial dysfunction, stem cell exhaustion. Boao Lecheng facilities offer physician-directed 5–7 day MSC + exosome + NAD+ combination programmes at USD 15,000–40,000, versus USD 50,000–100,000 at Swiss longevity clinics.
GMP-grade cleanroom used for MSC and CAR-T cell manufacturing at a licensed Chinese facility
On regulatory transparency: China's NMPA has approved four commercial cell therapy products (Relma-cel, Axi-cel, Equecab-cel, Zevorcabtagene autoleucel) — all CAR-T products for haematological malignancies. MSC therapies for non-cancer indications are in advanced clinical trial phases but do not yet hold commercial approval. The Boao Lecheng special zone creates a legally distinct pathway for supervised access before full NMPA approval.
How MSCs Work
Mesenchymal stem cells do not primarily replace damaged tissue. Their therapeutic value lies in paracrine signalling — the release of a rich secretome of growth factors, anti-inflammatory cytokines, and exosomes that modulate the local cellular environment.
This mechanism explains why MSCs show measurable effects across diverse conditions: osteoarthritis, Crohn’s disease, graft-versus-host disease, and metabolic disease all share a component of chronic inflammation that MSC-secreted molecules demonstrably suppress in published human trials.
Conditions & Applications
Who Travels to China for Stem Cell Therapy
Each condition has a distinct evidence level and clinical pathway. Click through for in-depth guides.
☆
Wellness — observational data
Anti-Aging & Longevity
MSC + exosome + NAD+ combination programmes targeting the hallmarks of ageing. Designed for healthy individuals aged 45–70 pursuing cellular optimisation. USD 15,000–40,000 at Boao Lecheng versus USD 50,000–100,000 at Swiss longevity clinics.
MSC infusion for metabolic restoration. A 2021 systematic review found average HbA1c reductions of 1.2–2.1% across randomised trials; 60% of treated patients reduced medication dosage at 12 months, with 15–20% achieving insulin independence. Available exclusively at Boao Lecheng.
MSC therapy for Crohn’s disease, lupus, rheumatoid arthritis, multiple sclerosis, and graft-versus-host disease. Chinese institutions including Ruijin and Tongji hospitals have published measurable disease activity reductions in Phase II trials. Available via registered ChiCTR trials.
Neural stem cell trials for Parkinson’s disease, ALS, and spinal cord injury are active across Chinese academic centres. Evidence is early-stage globally, not just in China. Evaluated case-by-case; patients must hold realistic expectations. China runs more active ALS and Parkinson’s trials than any other country.
MSC therapy for chronic obstructive pulmonary disease targets airway inflammation and alveolar repair via paracrine signalling. Chinese Phase II trials at institutions including Tongji Hospital (Wuhan) have reported improvements in FEV1 and 6-minute walk distance. Available via registered ChiCTR trials.
MSC protocols for liver cirrhosis, heart failure, knee osteoarthritis, and diabetic nephropathy are in active Chinese trials. Liver and cardiac applications have the strongest published data outside of HSCT. Available through registered trials at Grade 3A centres.
Established by State Council mandate in 2013 and significantly expanded under the “Nine National Policies” (国九条) framework, Boao Lecheng is a 20 km² medical pilot zone in Hainan where the rules are fundamentally different from mainland China.
Imported therapies before NMPA approval: Hospitals in the zone can use cell therapy products approved in the US, EU, Japan, or Australia — legally — before those products complete China’s domestic approval process, which typically adds 3–7 years.
Zero-tariff import: Medical devices and biological products enter the zone duty-free, reducing infrastructure and supply costs — one reason why programme pricing is lower than equivalent facilities in Japan or South Korea.
International patient infrastructure: Dedicated international patient departments, English-speaking clinical teams, and direct flight access from Singapore, Kuala Lumpur, Bangkok, and Hong Kong (2–3 hours).
NMPA oversight maintained: The zone is not a regulatory loophole. Facilities operate under ongoing NMPA and Hainan provincial health authority supervision. The difference is access timeline, not safety standards.
Clinical-grade cell therapy products prepared at a Boao Lecheng licensed facility
20km²
Zone area — dedicated international medical infrastructure
59
Countries with visa-free entry to Hainan for up to 30 days
2013
Year established by State Council mandate
3–7yrs
Regulatory time saved vs. standard NMPA mainland approval
China Care coordinates every step. You focus on getting well; we manage the logistics, translation, and hospital liaison.
01
Free Initial Consultation
Contact us with a brief summary of your condition, treatment history, and objectives. No medical records required at this stage. We respond within one business day with an honest assessment of whether treatment in China is likely to be appropriate for your situation — including cases where it is not.
24 hrsInitial response
02
Medical Record Review & Eligibility
You share your medical records (in any language — our team coordinates translation). We forward to the relevant specialist team for eligibility assessment. For most conditions, you receive a written preliminary eligibility assessment and treatment proposal within 3–7 business days.
3–7Business days
03
Visa & Travel Coordination
China Care prepares your medical visa documentation — including the hospital invitation letter required for your application. For Hainan travel, many nationalities qualify for visa-free entry. We arrange airport transfers, accommodation near the facility, and any interpreter services.
2–4Weeks lead time
04
On-Site Support Throughout Treatment
A China Care coordinator is reachable throughout your stay. We attend key appointments, ensure medical communication is clear, and handle any logistical issues that arise. Payment for treatment is made directly to the hospital.
FullDuration support
05
Post-Treatment Follow-Up
On discharge, you receive complete English-language medical documentation for handover to your home physician. For MSC and stem cell programmes, we coordinate the follow-up bloodwork schedule (typically at 30, 60, and 90 days) and facilitate remote consultation with the treating team if questions arise.
90-dayFollow-up window
Physician-directed MSC infusion preparation at a licensed Chinese clinical facility. Every programme China Care coordinates operates within registered trial or Boao Lecheng frameworks.
Cost Comparison — 2026
What Treatment Actually Costs
Costs below are estimates for international patients. Actual figures depend on condition severity, programme length, and institution. China Care provides itemised proposals after case review.
Treatment / Programme
China
USA / Switzerland
Regulation Status (China)
HSCT — allogeneic (blood cancer)
$30,000–$80,000
$300K–$900K (US)
Approved — standard of care
BCMA CAR-T — multiple myeloma
$80,000–$150,000
$465K–$600K (US)
NMPA-approved products
MSC therapy — Type 2 diabetes (Boao Lecheng)
$15,000–$35,000
$40K–$80K (Switzerland)
Boao Lecheng special zone
MSC therapy — autoimmune disease (trial)
Subsidised or free
Not commercially available
Registered ChiCTR trials
Anti-aging MSC + exosome programme (5–7 days)
$15,000–$40,000
$50K–$100K (Swiss clinics)
Boao Lecheng special zone
GPRC5D CAR-T — myeloma (post-BCMA failure)
$50,000–$100,000
Not yet commercially available
Active Chinese clinical trials
Figures are USD estimates for planning purposes (2026). Treatment costs are quoted directly by the hospital and are separate from China Care’s coordination fee. China Care never adds to, inflates, or marks up the hospital’s quoted treatment cost.
Condition-Specific Guides
Go Deeper on Your Situation
Each guide covers the clinical evidence, eligibility criteria, cost breakdown, and how to access treatment — written for patients and families, not clinicians.
It depends entirely on the type and setting. HSCT for blood cancers is standard approved medicine. CAR-T therapy has four NMPA-approved products for haematological malignancies. MSC therapy for conditions like diabetes and autoimmune disease is available either within registered clinical trials (legal and tracked on ChiCTR) or at Boao Lecheng under the zone’s special regulatory framework (also legal, under NMPA oversight). Unregistered clinics offering stem cell infusions outside of trials or the Boao zone exist in a grey area — and we do not work with them. Every programme we coordinate operates within one of these two legitimate frameworks.
What is the difference between a clinical trial and the Boao Lecheng programme?
+
In a registered ChiCTR clinical trial, you are a research participant. The trial covers most or all treatment costs, but you must meet specific eligibility criteria and follow the protocol exactly. Your data contributes to the science. In a Boao Lecheng zone programme, you are a paying patient receiving a supervised medical protocol under the zone’s special import and use regulations. You have more flexibility, the programme can be personalised, and you pay for it — but it is physician-directed and conducted at a licensed facility with full informed consent. Both are legitimate. Which is appropriate depends on your condition, eligibility, and objectives.
How do I know if I qualify for treatment?
+
The first step is a free enquiry through China Care’s contact form. We review your situation and, if appropriate, forward your records to the relevant specialist team for formal eligibility assessment. For most conditions we work with, a preliminary eligibility assessment can be completed within 3–7 business days of receiving your records. We also tell you honestly when treatment in China is unlikely to be appropriate for your situation — including cases where we recommend staying with your home oncologist or pursuing a different pathway.
Do I need a medical visa for Hainan / Boao Lecheng?
+
Hainan Province operates its own visa policies, separate from mainland China. Citizens of 59 countries — including the US, UK, Canada, Australia, and Singapore — currently qualify for visa-free entry to Hainan for up to 30 days. For other nationalities, or for patients travelling to mainland hospitals (Beijing, Shanghai, Guangzhou), a medical visa (M-visa) is required. China Care manages the full medical visa application process, including the hospital invitation letter. Full details are in our China medical visa guide.
What does China Care charge? How does the fee structure work?
+
China Care charges a fixed coordination fee — USD 2,000 for cancer treatment coordination and USD 3,500 for CAR-T or bone marrow transplant coordination. For executive health screening, you pay the published package rate through China Care — no extra fees added on top. Treatment costs are quoted directly by the hospital; China Care never adds to, inflates, or marks up those costs. Payment for treatment is made directly to the hospital.
Is the evidence for MSC anti-aging therapy strong enough to justify the investment?
+
This is the right question, and the honest answer is: it depends on your expectations and risk tolerance. MSCs reliably reduce markers of systemic inflammation in humans — one of the most replicated findings in clinical MSC research. Small observational studies in healthy ageing populations have reported improvements in energy, cognitive clarity, and joint comfort. What the evidence does not yet support is a guaranteed, quantified extension of lifespan or a proven reversal of biological age in large controlled trials. If you are a healthy 55-year-old treating your biology the way a serious athlete treats performance — with data, discipline, and realistic goals — the risk-benefit profile is reasonable. If you are hoping for a miracle, the evidence does not support it. We only work with Boao Lecheng facilities that are transparent about this distinction. Read the full anti-aging guide for an honest evidence summary.
Start Your Enquiry
The First Conversation Is Free. And Honest.
Tell us your situation. We’ll tell you whether treatment in China makes sense — and if it does, which programme, which hospital, and what it will cost.
